The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AKTX | -68.75% | -97.5% | -52.14% | -100% |
| S&P | +19.89% | +109.18% | +15.89% | +263% |
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $33.78M | 57.9% |
| Market Cap / Employee | $3.75M | 0.0% |
| Employees | 9 | 0.0% |
| Net Income | -$1.92M | 74.6% |
| EBITDA | -$3.16M | 43.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.77M | -33.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $1.55M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -43.90% | 0.0% |
| Return On Invested Capital | 558.89% | 44326.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.30M | 32.5% |
| Operating Free Cash Flow | -$3.30M | 32.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -9.68 | -2.21 | -2.25 | 1.55 | -68.38% |
| Price to Tangible Book Value | -9.68 | -2.21 | -2.25 | -1.31 | -126.44% |
| Enterprise Value to EBITDA | -18.86 | -7.70 | -9.38 | -11.28 | 194.81% |
| Return on Equity | -197.1% | -112.2% | - | ||
| Total Debt | $1.20M | $3.26M | $1.85M | $1.55M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
